Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)
18 Março 2022 - 7:30AM
Edgar (US Regulatory)
Filed
by Marrone Bio Innovations, Inc.
(Commission
File No. 001-36030)
Pursuant
to Rule 425 under the Securities Act of 1933, as amended
and
deemed filed under Rule 14a-12 under the
Securities
Exchange Act of 1934, as amended
Subject
Company: Marrone Bio Innovations, Inc. (Commission File No.: 001-36030)
Date:
March 18, 2022
The
following questions and answers were sent to employees of Marrone Bio Innovations, Inc. on March 17, 2022.
Important
Additional Information
In
connection with the proposed transaction, Bioceres Crop Solutions Corp. (“Bioceres”) will file a registration statement on
Form F-4 (the “registration statement”) with the Securities and Exchange Commission (“SEC”), which will contain
a proxy statement of Marrone Bio Innovations, Inc. (“MBI”), that also constitutes a prospectus of Bioceres (the “proxy
statement/prospectus”), and each party will file other documents regarding the proposed transaction with the SEC from time to time.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS
AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. When final,
a definitive copy of the proxy statement/prospectus will be sent to MBI stockholders. Investors and security holders will be able to
obtain the registration statement and the proxy statement/prospectus free of charge from the SEC’s website or from Bioceres or
MBI. The documents filed by Bioceres with the SEC may be obtained free of charge at Bioceres’ website, at www.biocerescrops.com,
or at the SEC’s website, at www.sec.gov. These documents may also be obtained free of charge from Bioceres by requesting
them by mail at Bioceres Crop Solutions Corp., Investor Relations, Ocampo 210 bis, Predio CCT, Rosario Province of Santa Fe, Argentina.
The documents filed by MBI with the SEC may be obtained free of charge at MBI’s website, at www.marronebio.com, or at the
SEC’s website, at www.sec.gov. These documents may also be obtained free of charge from MBI by requesting them by mail at
Marrone Bio Innovations, Inc., Investor Relations, 7780-420 Briar Creek Parkway, Raleigh, NC 27617, or by telephone at (530) 750-2800.
Participants
in the Solicitation
Bioceres
and MBI and their respective directors and executive officers and other members of management and employees may be deemed to be participants
in the solicitation of consents in respect of the proposed transaction. Information about Bioceres’ directors and executive officers
is available in Bioceres’ Annual Report on Form 20-F, filed with the SEC on October 29, 2021. Information about MBI’s directors
and executive officers is available in MBI’s proxy statement dated April 26, 2021, for its 2021 Annual Meeting of Stockholders,
and MBI’s Current Reports on Form 8-K, filed with the SEC on August 30, 2021 and February 22, 2022. Other information regarding
the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise,
will be contained in the registration statement, the proxy statement/prospectus and other relevant materials to be filed with the SEC
regarding the proposed transaction when they become available. Investors should read the proxy statement/prospectus carefully when it
becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Bioceres or MBI
using the sources as indicated above.
No
Offer or Solicitation
This
communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale
of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the
requirements of Section 10 of the U.S. Securities Act of 1933, as amended (the “Securities Act”).
Cautionary
Statement Regarding Forward-Looking Statements
This
communication contains certain “forward-looking” statements within the meaning of Section 27A of the Securities Act and Section
21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) concerning Bioceres, MBI and the proposed transaction
between Bioceres and MBI. All statements other than statements of fact, including information concerning future results, are forward-looking
statements. These forward-looking statements are generally identified by the words “anticipate,” “believe,” “estimate,”
“expect,” “seek,” “intend,” “may,” “could” or similar expressions. Such forward-looking
statements include, but are not limited to, statements about the benefits of the proposed transaction, including anticipated future financial
and operating results, synergies, accretion and growth rates, Bioceres’, MBI’s and the combined company’s plans, objectives,
expectations and intentions, and the expected timing of completion of the proposed transaction. There are several factors which could
cause actual plans and results to differ materially from those expressed or implied in forward-looking statements. Such factors include,
but are not limited to, the failure to obtain, or delays in obtaining, required regulatory approvals, and the risk that such approvals
may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the proposed
transaction, or the failure to satisfy any of the other conditions to the proposed transaction on a timely basis or at all; the occurrence
of events that may give rise to a right of one or both of the parties to terminate the business combination agreement; adverse effects
on the market price of Bioceres’ or MBI’s common stock and on Bioceres’ or MBI’s operating results because of
a failure to complete the proposed transaction in the anticipated timeframe or at all; the ability of Bioceres, MBI and the combined
company to make payments on debt or to repay existing or future indebtedness when due or to comply with the covenants contained therein;
adverse changes in the ratings of Bioceres’ debt securities or adverse conditions in the credit markets; negative effects of the
announcement, pendency or consummation of the transaction on the market price of Bioceres’ or MBI’s common stock and on Bioceres’
or MBI’s operating results, including as a result of changes in key customer, supplier, employee or other business relationships;
significant transaction costs, including financing costs, and unknown liabilities; failure to realize the expected benefits and synergies
of the proposed transaction in the expected timeframes or at all; costs or difficulties related to the integration of MBI’s technology
and operations into Bioceres; the risk of litigation or regulatory actions; the inability of Bioceres, MBI or the combined company to
retain and hire key personnel; the risk that certain contractual restrictions contained in the business combination agreement during
the pendency of the proposed transaction could adversely affect MBI’s ability to pursue business opportunities or strategic transactions;
effects of changes in the regulatory environment in which Bioceres and MBI operate; changes in global, political, economic, business,
competitive and market conditions; changes in tax and other laws and regulations; and other risks and uncertainties detailed in MBI’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections
thereof captioned “Risk Factors” and “Special Note Regarding Forward-Looking Statements and Trade Names,” as
well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.marronebio.com.
Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause
actual results and the timing of events to differ materially from those expressed in or implied by such forward-looking statements. Given
these risks and uncertainties, persons reading this communication are cautioned not to place undue reliance on such forward-looking statements.
MBI assumes no obligation to update or revise the information contained in this communication (whether as a result of new information,
future events, changes in its expectations, other circumstances that exist after the date as of which the forward-looking statements
were made or otherwise), except as required by applicable law.
Marrone Bio Innovations (NASDAQ:MBII)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Marrone Bio Innovations (NASDAQ:MBII)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024